: Microcrystalline Hydroxyapatite (MCHA):

Double Calcium Absorption & Increase Bone Density

Structural Integrity utilizes the most bioavailable form of calcium, Microcrystalline Hydroxyapatite Calcium (MCHC), plus the needed minerals and cofactors to support the bone matrix. MCHC is the ultimate calcium, made from life-source, organic calcium in its natural protein matrix from young, organically raised bovine-source raw bone. The complete protein matrix provides a nutritional source of the specific proteins needed for bone growth and repair, while increasing the surface area from which all the necessary bone-forming minerals are released. Additional fortification with boron further strengthens the new bone tissue.
Studies have shown that this form of calcium is superior to traditional calcium supplements. A study done with patients experiencing bone loss has shown an increase of 6.1% in cortical, or outer layer, bone density. The use of this form of calcium along with other forms will actually double the amount of calcium that is absorbed by stimulating the active absorption of calcium.

Here are some selected quotations on MCHC from peer reviewed clinical journals:

“Hydroxyapatite promotes positive cortical bone balance.”1

“Microcrystalline Hydroxyapetite compound did restore bone."2

“It was found that the whole-bone extract (Microcrystalline Hydroxyapatite) significantly increased absorption of the tracer suggesting that it is a valuable medium for calcium administration in metabolic bone disease.”3

“The results indicate that, with Microcrystalline Hydroxyapatite therapy, dramatic reductions in the symptoms (skeletal pain) in patients developing osteoporosis due to long term corticosteroid [e.g. cortisone, prednisone, etc.] treatment are associated with favorable biochemical and bone changes. . .”4

“The present results show that Microcrystalline Hydroxyapatite alone may be effective in reducing bone loss and possibly also in preventing fractures in patients with chronic active Hepatitis on long-term corticosteroid therapy.”5

“The results of this trial suggest that Microcrystalline Hydroxyapatite has a significant prophylactic effect in preventing the development of osteoporosis in corticosteroid treated rheumatoid patients.”6

In addition to all the naturally ocurring accompanying macro and trace minerals, such as magnesium, zinc, iron, potassium, silicon and manganese in the exact ratio needed for bone formation, each tablet of Structural Integrity supplies:

Component:	Quantity/Notes:
Boron	0.75 mg as Amino acid chelate to strengthen bone tissue
Calcium	250 mg, including 500 mg Microcrystalline Hydroxyapatite
Copper	0.5 mg as Amino acid chelate
Magnesium	125 mg from Magnesium oxide
Manganese	1.75 mg as Amino acid chelate
Phosphorus	125 mg as Microcrystalline Hydroxyapatite (ensuring an alkaline mineral to acid-forming phosphorus ratio of over 3:1)
Protein	Collagen, glycosaminoglycans (GAGs) & amino acids to form new bone matrix
Vitamin D	50 IU as cholecalciferol

One mineral that Structural Integrity does not supply is lead. In fact, even before the study came out a few years ago showing that over 80% of calcium supplements contain lead, every batch of Structural Integrity was already being assayed for lead to assure you of the best possible results.
In addition to supplementation with Structural Integrity, Dr. Swartwout recommends considering supplementation of the following hormones for the support of bone density restoration:

• Pregnenolone (tablets)
• 7-Keto DHEA (capsules) and/or
• Progesterone (as Progest E Complex sublingual drops).

1 Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, Hydroxyapatite and Calcium Gluconate in Treatment of Cortical Bone Thinning in Postmenopausal Women with Primary Biliary Cirrhosis, American Journal of Clinical Nutrition 1982; 36 426.
2 Dixon A S J. Non-Hormonal Treatment of Osteoporosis. British Medical Journal 1983; 286; 999.
3 Windsor A C M, Miscra D P, Loudon J M, Staddon C E. The Effect of Whole-Bone Extract on 47CA Absorption in the Elderly. Age and Aging 1987; 2; 230.
4 Pines A, Rasist H, Lynn A H, Whittington J. Clinical Trial of Microcrystalline Hydroxyapatite Compound in the Prevention of Osteoporosis Due to Corticosteroid Therapy. Current Medical Research and Opinion 1984; 8; 734.
5 Stellon A, Webb A, Williams R. Microcrystalline Hydroxyapatite in Prevention of Bone Loss in Corticosteroid Treated Patients with Chronic Active Hepatitis. Postgraduate Medical Journal 1985; 61; 791.
6 Nileen E M, Hayson M I V, Dixon A S J. Microcrystalline Hydroxyapatite Compound in Corticosteroid Treated Rheumatoid Patients; A Controlled Study. British Medical Journal 1978; 2; 1124.1 Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, Hydroxyapatite, and Calcium Gluconate in Treatment of Cortical Bone Thinning in Postmenopausal Women with Primary Biliary Cirrhosis, American Journal of Clinical Nutrition 1982; 36 426.